Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick blood test could spot ICU patients at highest risk of death

NCT ID NCT07184593

Knowledge-focused Sponsor: Erasme University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This observational study tests a new bedside device that measures nucleosome levels in the blood of critically ill ICU patients. Researchers want to see if these levels can predict which patients are likely to die within 30 days. The study will enroll 130 adults with conditions like sepsis, shock, severe trauma, or brain injury. It does not test any treatment, only a diagnostic tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a fast, bedside tool to predict which ICU patients are at highest risk of dying within 30 days, helping guide care decisions.
What could go wrong
This is an early observational study with only 130 participants. The test may not prove accurate enough for routine use, and results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of 130 adult critically ill patients admitted to the Intensive Care Unit (ICU) of Erasme Hospital. Eligible participants must be 18 years or older and admitted to the ICU within the past 24 hours. All patients must have arterial or central venous access for blood sampling. The population will include a diverse group of critically ill individuals representing various acute conditions commonly encountered in intensive care: Sepsis Septic shock Cardiogenic shock Severe trauma Acute brain injury Severe trauma Post-cardiac arrest shock Severe pancreatitis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Admission to the intensive care unit (ICU) within the past 24 hours. * Patient must meet one of the following conditions: Sepsis, defined according to SEPSIS-3 criteria. Septic shock, defined according to SEPSIS-3 criteria. Cardiogenic shock, classified as Stage C according to the Society for Cardiovascular Angiography and Interventions (SCAI). Severe trauma requiring transfusion of four or more units of red blood cells within six hours. Acute brain injury requiring invasive neuromonitoring. Post-cardiac arrest with at least 15 minutes of no or low perfusion. Severe acute pancreatitis requiring ICU-level care. \- Presence of an arterial or central venous catheter to allow blood sampling. Exclusion Criteria * Patient who has expressed opposition to participate. * Age younger than 18 years. * Imminent death with an expected survival of less than 24 hours. * Presence of therapeutic limitations (e.g., no indication for intubation). * Active cancer. * Absence of the required vascular access. * ICU admission longer than 24 hours prior to screening. * Readmission of a previously enrolled patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis brain injury cardiac arrest cardiogenic shock infectious disease with sepsis injury pancreatitis post-cardiac arrest syndrome Sepsis Shock, Cardiogenic toxic shock syndrome Wounds, Nonpenetrating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute brain injury Cardiac arrest (CA) Cardiogenic shock Pancreatitis Sepsis Septic shock Trauma blunt

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.